| 急性早幼粒细胞白血病耐药机制的研究进展 |
| |
| 引用本文： | 周晓丹. 急性早幼粒细胞白血病耐药机制的研究进展[J]. 白血病．淋巴瘤, 2017, 26(10). DOI: 10.3760/cma.j.issn.1009-9921.2017.10.016 |
| |
| 作者姓名： | 周晓丹 |
| |
| 作者单位： | 221002,徐州医科大学血液病研究所 徐州医科大学附属医院血液科 |
| |
| 基金项目： | 国家自然科学基金(81671584)National Natural Science Foundation of China |
| |
| 摘 要： | 全反式维甲酸(ATRA)与三氧化二砷(As2O3)作为一线药物治疗急性早幼粒细胞白血病(APL)以来,APL患者的治愈率得到显著提高.但ATRA和(或)As2O3耐药的出现成为一个严重问题.现就近年来新提出的一些耐药机制如融合基因突变、细胞信号通路异常、染色质重构复合物异常、凋亡调控异常、骨髓微环境介导耐药等方面进行综述.
|
| 关 键 词： | 白血病 早幼粒细胞 急性 抗药性 肿瘤 维甲酸 |
Progress of drug resistance mechanisms in acute promyelocytic leukemia |
| |
| Zhou Xiaodan. Progress of drug resistance mechanisms in acute promyelocytic leukemia[J]. Journal of Leukemia & Lymphoma, 2017, 26(10). DOI: 10.3760/cma.j.issn.1009-9921.2017.10.016 |
| |
| Authors: | Zhou Xiaodan |
| |
| Abstract: | Since all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) have become front-line drugs in treatment of acute promyelocytic leukemia (APL), cure rates of APL patients have improved dramatically. However, resistance to ATRA and/or As2O3has been a critical problem which has hampered the effect of treatment. In this review, some emerging mechanisms of resistance to ATRA and/or As2O3in recent years, such as genetic mutations, disorders of cellular signal transduction, disorders of chromatin remodeling complex, abnormal regulation of cell apoptosis, and micro-environment mediated drug resistance are summarized. |
| |
| Keywords: | Leukemia promyelocytic acute Drug resistance neoplasm Tretinoin |
| 本文献已被 万方数据 等数据库收录！ |
